NIPH Clinical Trials Search

28-day Repeated-dose Study of SCO-240

Basic Information

Recruitment status	Not Recruiting
Health condition(s) or Problem(s) studied	Pediatric growth hormone deficiency
Date of first enrollment	03/02/2026
Target sample size	18
Countries of recruitment
Study type	Interventional
Intervention(s)	Administer SCO-240 1 mg or 10 mg once daily for 28 days

Outcome(s)

Primary Outcome	Safety, Tolerability, and Pharmacodynamic
Secondary Outcome	NA

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	< 75age old
Gender	Male
Include criteria	- Gender: Male - At the time of informed consent, subjects in young adult group are aged >=18 and <65 and subject in older adult group are aged >=65 and <75. - Weight at screening: >=50 kg, body mass index (BMI) >=18.5 kg/m2 and =<25.0 kg/m2
Exclude criteria	- Subjects who have a present illness such as cardiovascular disease, central nervous system disease, gastrointestinal disease, hematopoietic disease, renal failure, metabolic or endocrine disorder, serious allergy, asthma, hypoxemia, hypertension, convulsion or allergic rash. For older adult group, conditions with mild severity and no anticipated changes in medications are acceptable.